Vascular endothelial growth factor (VEGF), mast cells and inflammation

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 2, 2013, Pages 327-335

  Shaik Dasthagirisaheb, Y B ^a   Varvara, G ^b   Murmura, G ^b   Saggini, A ^c   Potalivo, G ^d   Caraffa, A ^d   Antinolfi, P ^d   Tete S ^b   Tripodi, D ^b   Conti, F ^e   Cianchetti, E ^f   Toniato, E ^b   Rosati, M ^e   Conti, P ^b   Speranza, L ^b   Pantalone, A ^b   Saggini, R ^b   Theoharides, T C ^g   Pandolfi, Franco ^h  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e Pescara Hospital   (Italy)

^f Ortona Hospital   (Italy)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CATHOLIC UNIVERSITY   (Italy)

Author keywords

Inflammation; Mast cells; Vascular endothelial growth factor

Indexed keywords

CALCINEURIN; FIBROBLAST GROWTH FACTOR 2; FOCAL ADHESION KINASE; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; RANTES; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; CYTOKINE; EPIDERMAL GROWTH FACTOR; HEPARIN; IMMUNOGLOBULIN E ANTIBODY;

ANGIOGENESIS; APOPTOSIS; ARTERIOSCLEROSIS; CANCER PROGNOSIS; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; EYE DISEASE; HUMAN; INFLAMMATION; MAST CELL; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TUMOR MICROENVIRONMENT; AUTOIMMUNE DISEASE; CONTROL; CYTOKINE RELEASE; IMMUNITY; PROGNOSIS;

EID: 84881254421     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600206     Document Type: Review

References (101)

1. Brideau G, Mäkinen MJ, Elamaa H, Tu H, Nilsson G, Alitalo K, Pihlajaniemi T, Heljasvaara R. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007; 67(24):11528-35.
2. Carmeliet P, Ruiz de Almodovar C. VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration. Cell Mol Life Sci 2013; 70(10):1763-78.
3. Licht T, Keshet E. Delineating multiple functions of VEGF-A in the adult brain. Cell Mol Life Sci 2013;70(10):1727-37.
4. Koltowska K, Betterman KL, Harvey NL, Hogan BM. Getting out and about: the emergence and morphogenesis of the vertebrate lymphatic vasculature. Development 2013; 140(9):1857-70.
5. Hernández-Hernández OT, Camacho-Arroyo I. Regulation of gene expression by progesterone in cancer cells: effects on cyclin D1, EGFR and VEGF. Mini Rev Med Chem 2013; 13(5):635-42.
6. Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013; 31(3):787-97.
7. Lee KS, Kim SR, Park SJ, et al. Mast Cells Can Mediate Vascular Permeability through Regulation of the PI3K-HIF-1α-VEGF Axis. Am J Respir Crit Car Medi 2008; 178:787-97.
8. Solingen CV, Bijkerk R, de Boer HC, Rabelink TJ, Van Zonneveld AJ. The role of microRNA-126 in vascular homeostasis. Curr Vasc Pharmacol 2013; Epub ahead of print.
9. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012; 14(1):56-63.
10. Kirton JP, Xu Q. Endothelial precursors in vascular repair. Microvasc Res 2010; 79(3):193-9.
11. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 2009; 6(7):387-94.
12. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M. Mechanisms of vascular damage in SSc - implications for vascular treatment strategies. Rheumatology (Oxford) 2008; 47(S):v18-20.
13. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, Galli SJ. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fce receptor I expression. J Exp Med 1998; 188:1135-45. (Pubitemid 28443337)
14. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013; 33(S):S79-84.
15. Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 2012; 9(9):498-509.
16. Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012; 2012:948098.
17. Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H, Welker P, Lippert U, Henz BM, Moller A. Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 1998; 9:875-84. (Pubitemid 28173640)
18. Lubkowska A, Dolegowska B, Banfi G. Growth factor content in PRP and their applicability in medicine. J Biol Regul Homeost Agents 2012; 26(S):3S-22S.
19. Hartwig FP, Nedel F, Collares TV, Tarquinio SB, Nör JE, Demarco FF. Telomeres and tissue engineering: the potential roles of TERT in VEGF-mediated angiogenesis. Stem Cell Rev 2012; 8(4):1275-81.
20. 2 in human pterygium and normal conjunctiva: experimental study and review of the literature. Int J Immunopathol Pharmacol 2012; 25(3):607-15.
21. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-62.
22. Presta M, Andrés G, Leali D, Dell'Era P, Ronca R. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur Cytokine Netw 2009; 20(2):39-50.
23. Makinde T, Agrawal DK. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med 2008; 12(3):810-28. (Pubitemid 351718065)
24. Makinde T, Agrawal DK. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med 2008; 12(3):810-28. (Pubitemid 351718065)
25. Dethelfsen SM, Matsumura N, Zetter BR. Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Invasion Metastasis 1994; 14:395-408.
26. Presta M, Andrés G, Leali D, Dell'Era P, Ronca R. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur Cytokine Netw 2009; 20(2):39-50.
27. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011; 63(1):1-9.
28. Imoukhuede PI, Dokun AO, Annex BH, Popel AS. Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2013; 304(8):H1085-93.
29. Hag AM, Pedersen SF, Christoffersen C, Binderup T, Jensen MM, Jørgensen JT, Skovgaard D, Ripa RS, Kjaer A. (18)F-FDG PET imaging of murine atherosclerosis: association with gene expression of key molecular markers. PLoS One 2012; 7(11):e50908.
30. Sharma B, Albig AR. Matrix Gla protein reinforces angiogenic resolution. Microvasc Res 2013; 85:24-33.
31. Nienartowicz A, Sobanice-Lotowska ME, Jarocka-Cyrta E, Lemancewicz D. Mast cells in neoangiogenesis. Med Sci Monit 2006; 12: RA53-RA56. (Pubitemid 43332275)
32. Sasahira T, Ueda N, Kurihara M, Matsushima S, Ohmori H, Fujii K, Bhawal UK, Yamamoto K, Kirita T, Kuniyasu H. Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma. Hum Pathol. 2013; 44(6):1098-106.
33. Spinetti G, Fortunato O, Caporali A, et al. MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res 2013; 112(2):335-46.
34. Indraccolo S. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors. Adv Exp Med Biol 2013; 734:37-52.
35. Andreou K, Rajendran R, Krstic-Demonacos M, Demonacos C. Regulation of CXCR4 gene expression in breast cancer cells under diverse stress conditions. Int J Oncol. 2012; 41(6):2253-9.
36. Huang S, Yang N, Liu Y, Hu L, Zhao J, Gao J, Li Y, Li C, Zhang X, Huang T. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling. Nutr Res 2012; 32(7):530-6.
37. Ozdemir O. Mast cells and the tumor-associated neoangiogenesis. Med Sci Monit 2006; 12:LE9-LE11.
38. Anselmi F, Orlandini M, Rocchigiani M, De Clemente C, Salameh A, Lentucci C, Oliviero S, Galvagni F. c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. Angiogenesis 2012; 15(2):187-97.
39. Martini D, Monte MD, Ristori C, Cupisti E, Mei S, Fiorini P, Filippi L, Bagnoli P. Antiangiogenic effects of β2 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem 2011; 119(6):1317-29.
40. Tarallo V, Tudisco L, De Falco S. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. Am J Cancer Res 2011; 1(2):265-74.
41. Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood 2011; 117(5):1751-60.
42. Meco D, Servidei T, Zannoni GF, Martinelli E, Prisco MG, de Waure C, Riccardi R. Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma. Transl Oncol 2010; 3(5):326-35.
43. de Boer AG, Breimer DD. Cytokines and blood-brain barrier permeability. Prog Brain Res 1998; 115:425-51. (Pubitemid 28264333)
44. Ranieri G, Pantaleo M, Piccinno M, Roncetti M, Mutinati M, Marech I, Patruno R, Rizzo A, Sciorsci RL. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review. Crit Rev Oncol Hematol 2013; doi:pii: S1040-8428(13)00103-0.
45. Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Bioorg Med Chem Lett 2013; 23(13):3732-7.
46. Xi L, Zhang JQ, Liu ZC, Zhang JH, Yan JF, Jin Y, Lin J. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking. Org Biomol Chem 2013; 11(26):4367-78.
47. Niwakawa M, Yamaguchi R, Onozawa Y, Yasui H, Taku K, Naito T, Akinaga S, Boku N, Yamamoto N. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. Cancer Sci 2013; Epub ahead of print.
48. Yamagishi N, Teshima-Kondo S, Masuda K, Nishida K, Kuwano Y, Dang DT, Dang LH, Nikawa T, Rokutan K. Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. BMC Cancer 2013; 13:229.
49. Dabbous MK, Walker R, Haney L, Carter LM, Nicolson GL, Woolley DE. Mast cells and matrix degradation at sites of tumor invasion in rat mammary adenocarinoma. Br J Cancer 1986; 54:459-65. (Pubitemid 16031549)
50. Wu Y, Zhu Z. Vascular endothelial growth factor receptor 1, a therapeutic target in cancer, inflammation and other disorders. Curr Med Chem 2009; 16(22):2890-8.
51. Band M, Shams I, Joel A, Avivi A. Cloning and in vivo expression of vascular endothelial growth factor receptor 2 (Flk1) in the naturally hypoxia-tolerant subterranean mole rat. FASEB J 2008; 22(1):105-12.
52. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003; 31(Pt 6):1171-7. (Pubitemid 38030933)
53. Gold LI, Rahman M, Blechman KM, et al. Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects. J Investig Dermatol Symp Proc 2006; 11(1):57-65. (Pubitemid 44413145)
54. Hebda JK, Leclair HM, Azzi S, Roussel C, Scott MG, Bidère N, Gavard J. The C-terminus region of β-arrestin1 modulates VE-cadherin expression and endothelial cell permeability. Cell Commun Signal 2013; 11(1):37.
55. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005; 6:135-42. (Pubitemid 40268194)
56. Etulain J, Fondevila C, Negrotto S, Schattner M. Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol 2013; Epub ahead of print.
57. Yan C, Wang C, Dong M, Liu S, Qi C, Zhao Y. RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells. Oncol Lett 2013; 5(3):1031-35.
58. Jiang ZY, Qin SK, Yin XJ, Chen YL, Zhu L. Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model. Exp Ther Med 2012; 4(2):277-284.
59. Hu W, Xia LJ, Chen FH, Wu FR, Tang J, Chen CZ, Jiang S, Chen HH. Recombinant human endostatin inhibits adjuvant arthritis by down-regulating VEGF expression and suppression of TNF-α, IL-1β production. Inflamm Res 2012; 61(8):827-35.
60. v mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988; 42:48-52.
61. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001; 354(Pt 2):233-42. (Pubitemid 32209858)
62. Prats AC, Van den Berghe L, Rayssac A, et al. CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis. Microvasc Res 2013; Epub ahead of print.
63. Yari K, Afzali S, Mozafari H, Mansouri K, Mostafaie A. Molecular cloning, expression and purification of recombinant soluble mouse endostatin as an anti-angiogenic protein in Escherichia coli. Mol Biol Rep 2013; 40(2):1027-33.
64. Yokoyama Y, Ramakrishnan S. Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer 2007; 121(11):2402-9. (Pubitemid 350022409)
65. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 2007; 101:851-61. (Pubitemid 47040867)
66. Lee WY, Wang CJ, Lin TY, Hsiao CL, Luo CW. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. Am J Physiol Endocrinol Metab 2013; 304(1):E32-40.
67. Wang D, Gilbert JR, Cray JJ Jr, Kubala AA, Shaw MA, Billiar TR, Cooper GM. Accelerated calvarial healing in mice lacking Toll-like receptor 4. PLoS One 2012; 7(10):e46945.
68. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. Science 1996; 271:818-22. (Pubitemid 26058936)
69. De Groot J, Reardon DA, Batchelor TT. Antiangiogenic therapy for glioblastoma. Am Soc Clin Oncol Educ Book 2013; 2013:71-78.
70. Jeong SJ, Han SH, Kim CO, Choi JY, Kim JM. Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care 2013; 17(3):R97. Epub ahead of print.
71. Bradshaw M, Mansfield A, Peikert T. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep 2013; 15(3):207-16.
72. Reubi JC, Waser B, Vale W, Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 2003; 88:3312-20. (Pubitemid 36877510)
73. Lin ML, Chung JG, Lu YC, Yang CY, Chen SS. Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells in vitro by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor. Oral Oncol. 2009; 45(6):531-7.
74. Kim I, Ryu YS, Kwak HJ, Ahn SY, Oh JL, Yancopoulos GD, Gale NW, Koh GY. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J 2002; 16(9):1126-8.
75. Chang LH, Pan SL, Lai CY, Tsai AC, Teng CM. Activated PAR-2 Regulates Pancreatic Cancer Progression through ILK/HIF-α-Induced TGF-α Expression and MEK/VEGF-A-Mediated Angiogenesis. Am J Pathol 2013; Epub ahead of print.
76. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118:560-70. (Pubitemid 351206546)
77. Tawfik A, Al-Shabrawey M, Roon P, Sonne S, Covar JA, Matragoon S, Ganapathy PS, Atherton SS, El-Remessy A, Ganapathy V, Smith SB. Alterations of retinal vasculature in cystathionine-Beta-synthase mutant mice, a model of hyperhomocysteinemia. Invest Ophthalmol Vis Sci 2013; 54(2):939-49.
78. Liu H, Zhang W, Xu Z, Caldwell RW, Caldwell RB, Brooks SE. Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol Vis Sci 2013; 54(2):918-31.
79. Dal Monte M, Filippi L, Bagnoli P. Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedebergs Arch Pharmacol 2013; 386(4):269-78.
80. Ito T, Komeima K, Yasuma T, Enomoto A, Asai N, Asai M, Iwase S, Takahashi M, Terasaki H. Girdin and its phosphorylation dynamically regulate neonatal vascular development and pathological neovascularization in the retina. Am J Pathol 2013; 182(2):586-96.
81. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013; 120(1):106-14.
82. Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002; 303:1061-66. (Pubitemid 35424390)
83. Owen LA, Hartnett ME. Soluble Mediators of Diabetic Macular Edema: The Diagnostic Role of Aqueous VEGF and Cytokine Levels in Diabetic Macular Edema. Curr Diab Rep 2013; Epub ahead of print.
84. Lee WJ, Kang MH, Seong M, Cho HY. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 2012; 96(11):1426-30.
85. Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 2012; 90(2):e98-e103.
86. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, Nam DH. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152(4):686-94.
87. della Rovere F, Granata A, Familiari D, D'Arrigo G, Mondello B, Basile G. Mast cells in invasive ductal breast cancer: different behavior in high and minimum hormone-receptive cancers. Anticancer Res 2007; 27:2465-71. (Pubitemid 47228090)
88. Terrasi M, Bazan V, Caruso S, et al. Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. J Cell Physiol 2013; 228(6):1368-74.
89. Chen CT, Du Y, Yamaguchi H, Hsu JM, Kuo HP, Hortobagyi GN, Hung MC. Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther 2012; 11(10):2212-21.
90. Price RS, Cavazos DA, De Angel RE, Hursting SD, deGraffenried LA. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis 2012;1 5(2):135-43.
91. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology 1998; 139:403-13. (Pubitemid 28166335)
92. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem 2013; 288(14):10093-9.
93. Wen J, Zhao Y, Li J, Weng C, Cai J, Yang K, Yuan H, Imperato-McGinley J, Zhu YS. Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Prostate 2013; 73(10):1069-81.
94. Jensen LD, Cao Y. Clock controls angiogenesis. Cell Cycle 2013; 12(3):405-8.
95. Zhang J, Ye J, Ma D, Liu N, Wu H, Yu S, Sun X, Tse W, Ji C. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Carcinogenesis 2013; 34(3):667-77.
96. Lang UE, Borgwardt S. molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem 2013; 31(6):761-77.
97. Theoharides TC, Spanos CP, Pang X, et al. Stress-induced intracranial mast cell degranulation. A corticotropin-releasing hormone-mediated effect. Endocrinology 1995; 136:5745-50.
98. O'Connor JP, Jayson GC. Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res 2012; 18(24):6588-98.
99. Lang UE, Borgwardt S. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cell Physiol Biochem 2013; 31(6):761-77.
100. Ribatti D. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. Immunol Lett 2013; 152(2):83-88.
101. Gyanchandani R, Sano D, Ortega Alves MV, Klein JD, Knapick BA, Oh S, Myers JN, Kim S. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol 2013; Epub ahead of print.